Investigational Telitacicept Significantly Improves Myasthenia Gravis Outcomes in Phase 3 Study

In a late-stage trial, telitacicept demonstrated significant and rapid clinical improvements in gMG, achieving notable symptom reductions, improved quality of life, and strong safety outcomes.:

Source: Neurology Read More